Dear Ms. Tegtmeyer:

Please refer to your Supplemental New Drug Applications (sNDA), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Product</th>
<th>Submitted on:</th>
<th>Received on:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 21035/S-099</td>
<td>Keppra (levetiracetam) Tablets</td>
<td>March 21, 2017</td>
<td>March 21, 2017</td>
</tr>
<tr>
<td>NDA 21505/S-038</td>
<td>Keppra (levetiracetam) Oral Solution</td>
<td>March 21, 2017</td>
<td>March 21, 2017</td>
</tr>
<tr>
<td>NDA 21872/S-023</td>
<td>Keppra (levetiracetam) Injection</td>
<td>March 21, 2017</td>
<td>March 21, 2017</td>
</tr>
<tr>
<td>NDA 22285/S-025</td>
<td>Keppra (levetiracetam) XR Tablets</td>
<td>March 21, 2017</td>
<td>March 21, 2017</td>
</tr>
</tbody>
</table>

These “Changes Being Effected” supplemental new drug applications provide for the addition of a new Warnings and Precautions subsection of the prescribing information describing the risk for anaphylaxis and angioedema with Keppra. The supplements also provide for corresponding revisions to the Contraindications, Adverse Reactions, and Patient Counseling Information sections, and to the Medication Guide.
**APPROVAL & LABELING**

We have completed our review of these supplemental applications and their amendments. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirements for these applications.
All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Brenda Reggettz, PharmD, by email at Brenda.Reggettz@fda.hhs.gov or by phone at (240) 402-6220.

Sincerely,

{See appended electronic signature page}

Alice Hughes, M.D.
Deputy Director for Safety
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALICE HUGHES
04/24/2017